France Point of Care Diagnostics Market: By Product (Glucose Testing, Cardiac Markers, Infectious Disease Testing, Pregnancy & Fertility Testing, Hematology Testing, and Others), By Technology (PCR-based, Hybridization-based, Genetic Sequencing-based, Microarray-based), By End-User (Hospital Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, and Home & Self-testing) region Forecast 2019 - 2030

France Point of Care Diagnostics Market size was valued at US$ 102.3 million in 2023 and is projected to reach a value of US$ 195.6 million by 2030, at a CAGR of 9.7% from 2024-2030.  The prevalence of chronic diseases, such as diabetes, rheumatism, or cancer, is increasing due to a variety of reasons, including the aging of the world's population, sedentary lifestyles, unhealthy food habits, and environmental factors. Similarly, the prevalence of infectious diseases such as H. pylori, HIV, tuberculosis, and Hepatitis C is increasing day by day in developed as well as developing economies.  Point-of-care diagnostics is widely being adopted by different patients in the world where tests are conducted by collecting samples from the patient's location, and results can be obtained in highly minimal time because of the application of micro fluids, chips, and nano diagnostics.

Key Players

The French Point of Care Diagnostics market is led by Roche Diagnostics, with a widely expanded portfolio of in-vitro diagnostic solutions; Abbott Laboratories, testing product innovation leader; and Siemens Healthineers, leader in the point-of-care devices area. Thermo Fisher Scientific shines in developing advanced diagnostic solutions; Cepheid, rapid molecular diagnostics; and, with its hemoglobin testing leadership, HemoCue completes the profile. The developer of rapid testing solutions is Abbott Rapid Diagnostics. PerkinElmer is a leader in newborn screening technology. bioMérieux focuses on microbiology diagnostics. A. The two companies, taken collectively, are moving forward by developing innovation and making it more accessible through Menarini Diagnostics.

Key Takeaways

•    On the basis of product, the market is segmented into glucose testing, cardiac markers, infectious disease testing, pregnancy & fertility testing, hematology testing, and others. 
•    PCR-based segment emerged as the market leader in the technology segment of the point-of-care molecular diagnostics market
•    By end-user, the market for point-of-care diagnostics has been categorized into hospital bedside, physician's office lab, urgent care & retail clinics, and home & self-testing

Facts & Figures

• By March 2022, approximately 20% of all diagnostic tests in France were performed at the point of care, reflecting a shift towards more immediate testing solutions.
• Studies published in June 2023 showed that point-of-care testing can reduce turnaround time for results by up to 70%, improving patient management and outcomes.
• As of January 2021, there were over 3,000 point-of-care testing sites established across France to enhance accessibility for patients.

Key Developments

• In August 2023: Companies like Thermo Fisher Scientific introduced remote monitoring technologies integrated with point-of-care diagnostics to improve patient management and data collection.
• In February 2023: The French regulatory agency granted approvals for several new point-of-care testing devices, enhancing options for rapid diagnostics in clinical settings.

France Point of Care Diagnostics Market Segmentation

By Product Type: Based on product, the market is segmented into glucose testing, cardiac markers, infectious disease testing, pregnancy & fertility testing, hematology testing, and others. Blood glucose Testing accounted for the highest share of the global point-of-care diagnostics market. Increasing incidence of diabetes among individuals and the shift of market competitors towards product development and launch with advanced technology, features, and functionality, are some of the significant factors driving growth in the segment.

By Technology: The PCR-based segment emerged as the market leader in the technology Segment. The preference for PCR-based diagnostics lies in their exceptional sensitivity and specificity, coupled with the capability to deliver results as quickly as possible. hybridization-based technologies have carved out a quite significant niche. These diagnostics are valued for their accuracy in the detection of a particular DNA or RNA sequence and are increasingly being used for the detection of genetic mutations as well as infectious diseases. Genetic sequencing-based diagnostics, like microarray-based diagnostics, are also being developed and are likely to hold market share very rapidly though both of these currently hold smaller percentages of market share. 

By End-User: the market for point-of-care diagnostics has been categorized into hospital bedside, physician's office lab, urgent care & retail clinics, and home & self-testing. Hospital bedside dominated the market in 2023. The increasing adoption of advanced point-of-care testing devices and instruments in hospitals of developed nations, the development in the healthcare infrastructure, and increasing investments made by public and private sectors in emerging countries due to rising healthcare expenditure among these countries are some of the vital factors fuelling the growth of the segment in the market.